Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
Background: We assessed the anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine in Japanese hemodialysis patients and determined factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine.
Methods: Overall, 64 patients (37 males, 27 females; mean age 71.4 ± 11.7 years) were enrolled in this single-center, prospective, longitudinal study. Anti-SARS-CoV-2 spike antibody titers were compared between hemodialysis patients and 18 healthcare workers (8 males, 10 females; mean age 45.9 ± 12.2 years). Multiple linear regression analysis was used to identify factors associated with the anti-SARS-CoV-2 spike antibody titer after the third vaccination.
Results: There was no significant difference in anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination between hemodialysis patients and healthcare workers (18,500 [interquartile range, 11,000-34,500] vs. 11,500 [interquartile range, 7,918-19,500], all values in AU/mL; p = 0.17). Uric acid (standard coefficient [β] = -0.203, p = 0.02), transferrin saturation (β = -0.269, p = 0.003), and log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.440, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination. In contrast, only the log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.410, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 12 weeks after the third vaccination.
Conclusion: The anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine was comparable between hemodialysis patients and healthcare workers. Uric acid concentration, transferrin saturation, and anti-SARS-CoV-2 spike antibody titer before the third dose were associated with the anti-SARS-CoV-2 spike antibody titer after the third dose in Japanese hemodialysis patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Kidney research and clinical practice - (2024) vom: 19. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirai, Keiji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-severe acute respiratory syndrome coronavirus 2 spike antibody |
|---|
| Anmerkungen: |
Date Revised 23.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.23876/j.krcp.23.121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368791343 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368791343 | ||
| 003 | DE-627 | ||
| 005 | 20240229145026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23876/j.krcp.23.121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM368791343 | ||
| 035 | |a (NLM)38389151 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirai, Keiji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Background: We assessed the anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine in Japanese hemodialysis patients and determined factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine | ||
| 520 | |a Methods: Overall, 64 patients (37 males, 27 females; mean age 71.4 ± 11.7 years) were enrolled in this single-center, prospective, longitudinal study. Anti-SARS-CoV-2 spike antibody titers were compared between hemodialysis patients and 18 healthcare workers (8 males, 10 females; mean age 45.9 ± 12.2 years). Multiple linear regression analysis was used to identify factors associated with the anti-SARS-CoV-2 spike antibody titer after the third vaccination | ||
| 520 | |a Results: There was no significant difference in anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination between hemodialysis patients and healthcare workers (18,500 [interquartile range, 11,000-34,500] vs. 11,500 [interquartile range, 7,918-19,500], all values in AU/mL; p = 0.17). Uric acid (standard coefficient [β] = -0.203, p = 0.02), transferrin saturation (β = -0.269, p = 0.003), and log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.440, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination. In contrast, only the log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.410, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 12 weeks after the third vaccination | ||
| 520 | |a Conclusion: The anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine was comparable between hemodialysis patients and healthcare workers. Uric acid concentration, transferrin saturation, and anti-SARS-CoV-2 spike antibody titer before the third dose were associated with the anti-SARS-CoV-2 spike antibody titer after the third dose in Japanese hemodialysis patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-severe acute respiratory syndrome coronavirus 2 spike antibody | |
| 650 | 4 | |a BNT162b2 messenger RNA vaccine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hemodialysis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Shimotashiro, Masako |e verfasserin |4 aut | |
| 700 | 1 | |a Okumura, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ookawara, Susumu |e verfasserin |4 aut | |
| 700 | 1 | |a Morishita, Yoshiyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney research and clinical practice |d 2012 |g (2024) vom: 19. Feb. |w (DE-627)NLM230042112 |x 2211-9132 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23876/j.krcp.23.121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 02 | ||